Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP)
- 15 December 1978
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 240 (25), 2743-2746
- https://doi.org/10.1001/jama.240.25.2743
Abstract
Patients (54) with metastatic non-oat-cell bronchogenic carcinoma were treated with (CAMP). Of 51 of these patients, 18 with measurable disease showed an objective response to CAMP chemotherapy, with a median survival of 12.6 mo. Of the 18 patients 8 were still alive, and 2 have been in continuous remission for 20 and 26 mo. Survival for patients with stable disease was 12 mo., similar to that for patients demonstrating objective regression in response to CAMP treatment. Weight loss, performance status and dominant site of metastases proved to be important prognostic factors. The CAMP regimen was well tolerated; there were only 2 drug-related deaths, both secondary to infectious complications.This publication has 7 references indexed in Scilit:
- Chemotherapy for Bronchogenic CarcinomaJAMA, 1977
- Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristineCancer, 1976
- Combination chemotherapy in advanced lung cancer with increased survivalCancer, 1976
- SMALL-CELL CARCINOMA OF THE LUNG: ATTEMPT TO REMEDY CAUSES OF PAST THERAPEUTIC FAILUREThe Lancet, 1976
- Bacon (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patientsCancer, 1976
- BLEOMYCIN (NSC-125066) FOLLOWED BY CYCLOPHOSPHAMIDE (NSC-26271), VINCRISTINE (NSC-67574), METHOTREXATE (NSC-740), AND 5-FLUOROURACIL (NSC-19893) FOR NON-OAT CELL BRONCHOGENIC CARCINOMA1976
- CYCLOPHOSPHAMIDE, ADRIAMYCIN, METHOTREXATE, AND PROCARBAZINE (CAMP)-EFFECTIVE 4-DRUG COMBINATION CHEMOTHERAPY FOR METASTATIC NON-OAT CELL BRONCHOGENIC CARCINOMA1976